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COMETa b s t r a c t
Recent in vitro work using puriﬁed enzymes demonstrated that nicotine and/or a nicotine metabolite
could inhibit CYPs (CYP2A6, 2A13, 2E1) involved in the metabolism of the genotoxic tobacco nitrosamine
NNK. This observation raises the possibility of nicotine interaction with the mechanism of NNK
bioactivation. Therefore, we hypothesized that nicotine or a nicotine metabolite such as cotinine might
contribute to the inhibition of NNK-induced DNA strand breaks by interfering with CYP enzymes. The
effect of nicotine and cotinine on DNA strand breaks was evaluated using the COMET assay in CYP
competent HepaRG cells incubated with bioactive CYP-dependent NNK and CYP-independent NNKOAc
(4-(acetoxymethylnitrosoamino)-1-(3-pyridyl)-1-butanone). We report a dose-dependent reduction in
DNA damage in hepatic-derived cell lines in the presence of nicotine and cotinine. Those results are
discussed in the context of the in vitro model selected.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
The tobacco-speciﬁc nitrosamine, NNK (4-(methylnitrosami-
no)-1-(3-pyridyl)-1-butanone) (Fig. 1) originates from nicotine
during the curing of tobacco (nitrosation of nicotine). NNK is a class
1 IARC carcinogen, indicating that it is a human carcinogen
(Cogliano et al., 2004). NNK has been strongly linked to the aetiol-
ogy of lung adenocarcinoma in humans, and in lung, liver, nasal,
and pancreatic tumors in rodents (Hecht et al., 1994; Hecht,
1998, 1999, 2002; Hoffmann et al., 1996).
The metabolism of NNK follows two distinct routes, namely car-
bonyl reduction and a-hydroxylation, which occur simultaneously
in the respiratory tract and the liver (Fig. 1). These reactions are
catalyzed by a variety of phase I metabolic enzymes (Hecht et al.,
1994; Hecht, 1998; Maser, 1998; Smith et al., 1992, 1995). Directa-hydroxylation is one major bioactivation pathway for NNK, gen-
erating two DNA-reactive intermediates and their ﬁnal products 4-
oxo-4-(3-pyridyl) 1-butanol (HPB) (Fig. 1) and 4-oxo-4-(3-pyridyl)
butanone (OPB) (Fig. 1) (Smith et al., 1999, 1992). Microsome-
based experiments demonstrated that CYP1A2, 2A6, 2B6, 2D6,
2E1, 3A4 and 3A5 (Hecht, 1998; Jalas et al., 2005; Smith et al.,
1992) are active towards NNK in liver. CYP1A2, CYP2B6, CYP3A4,
CYP2A6, and CYP2E1 can bioactivate NNK and their relative
abundance in the liver suggests that they could play a role in
NNK a-hydroxylation in this tissue (Jalas et al., 2005). Due to the
selective high level of mRNA expression of CYP2A13 in airway
epithelium and favorable kinetics data this enzyme has been the
focus of many studies aiming at characterising the bioactivation
of NNK in the lung (He et al., 2004; Su et al., 2000). NNK carcino-
genicity has been clearly established in systems using doses of a
single chemical (Hecht, 1998). However, bioactivation of toxicants
is ultimately the result of a complex series of chemical interactions
with metabolic pathways. Interestingly recent publications have
highlighted the complex and potentially diverging effects of such
chemical interactions. In vivo work using A/J mice has suggested
a protective effect of nicotine against metabolic activation of
NNK (Brown et al., 1999), however the mechanism was not identi-
ﬁed. In contrast, another in vivo study conducted with A/J mice and
a K-ras mutant strain treated with NNK and nicotine concluded
Fig. 1. Simpliﬁed representation of NNK metabolism detailing the a-hydroxylation route. DNA reactive intermediates are marked by a ‘#’ symbol.
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progression (Maier et al., 2011; Murphy et al., 2011). Yet, a number
of publications using in vitro systems have reported that nicotine
or a nicotine metabolite were inhibitors of diverse CYPs involved
in NNK bioactivation including CYP2A6, 2A13, and 2E1.
More speciﬁcally, in vitro work using puriﬁed enzymes have
demonstrated that nicotine or a nicotine metabolite could protect
against CYP2A13/2A6-dependent NNK bioactivation (Bao et al.,
2005; von Weymarn et al., 2006). Further investigation identiﬁed
the nicotine D5
0(10) iminium ion as a mechanism based inhibitor
of CYP2A6 and CYP2A13 (von Weymarn et al., 2012). b-nicotyrine,
a nicotine related alkaloid, has also been shown to inhibit CYP2A6
and CYP2A13 in vitro (Denton et al., 2004; Kramlinger et al., 2012).
CYP2E1 which has been shown to activate nitrosamines in human
and rat liver (Yamazaki et al., 1992) is also inhibited by nicotine
and cotinine, albeit modestly (Van Vleet et al., 2001). Interestingly
cotinine is an uncompetitive inhibitor of CYP2E1 which indicates
that nicotine or a nicotine metabolite does not necessarily have
to be an enzyme substrate to exert an inhibitory activity (Van
Vleet et al., 2001). In the context of tobacco-smoke chemical
interactions and toxicological assessment, the nicotine-dependent
inhibition of CYPs raises an interesting and potentially controver-
sial question regarding the possibility that nicotine or nicotine
metabolites could protect against some form of NNK-induced
DNA damage. Therefore we hypothesized that nicotine or cotinine
might inhibit CYP-dependent NNK-induced DNA single and
double-strand breaks in metabolically competent cells. The effect
of nicotine, cotinine and an isothiocyanate control on DNA damage
was compared using the COMET assay in metabolically activeHepaRG cells incubated with bioactive CYP-independent NNKOAc
and bioactive CYP-dependent NNK. The results are presented and
discussed in the context of recent in vitro and in vivo data looking
at the complex interaction of nicotine and nitrosamines.2. Materials and methods
2.1. Chemicals and reagents
NNKOAc [(Acetoxymethyl)nitrosamino]-1-(3-pyridyl)-1-buta-
none] (NNKOAc; CAS No. 127686-49-1) and 3-Phenylpropyl isothi-
ocyanate (PPITC; CAS No. 2627-27-2) were obtained from Santa
Cruz Biotechnology, Inc. (Heidelberg, Germany). Cotinine (CAS
No. 486-56-6), Methyl methanesulfonate (MMS; CAS No. 66-27-
3) and all other reagents required for the COMET assay were
purchased from Sigma Aldrich (Madrid, Spain). Pooled lung mRNA
(5 subjects) was supplied by BioChain (Newark, USA).2.2. Cell line and culture conditions
Human hepatic CYP-competent HepaRG cells were obtained
from Merck Millipore (catalog number: MMHPR116). Seven days
prior to treatment, cells were seeded on BioCoat™ Collagen I
24-well plates (Becton Dickinson, S.A.) at 0.48  106 viable cells/
well and maintained according to the manufacturer’s instructions.
HBEC cells at passage 1 from three non-smoker male donors were
obtained from Lonza (Lonza Group Ltd., Switzerland) (Donor 1
(D1): 44 years old; donor 2 (D2): 39 years old, donor 3 (D3):
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A549 cell lines were obtained from the American Type Culture
Collection (ATCC, USA). Cells were cultured according to the man-
ufacturer’s instructions at 37 C 5% CO2 in a humidiﬁed incubator.
2.3. Quantitative RT-PCR
The procedure followed for the QRT-PCR assay is detailed in
Garcia-Canton et al. (2013). A Ct threshold of 36 was selected
above which a gene is considered to be not expressed. Threshold
cycle (Ct) values for the genes were normalized to RPLP0, GAPDH,
and B2 M. DCt values were imported into JMP Genomics 6.0 to
generate the heat map using an unsupervised clustering approach.
2.4. CYP2A6 activity assay
Three replicates per condition were incubated for 4 h with
100 lM coumarin (ﬁnal data were reported as the formation of 7-
hydroxycoumarin pmol/mg protein/min). For inhibited conditions,
the CYP2A family inhibitor 8-methoxypsoralen was used at a ﬁnal
concentration of 10 lM. Following incubation with coumarin,
250 ll of basal medium was adjusted to pH 4.5–5.0 with
hydrochloric acid and treated with ß-glucuronidase from Helix
pomatia for 12 h at 37 C. Following the glucuronidase treatment,
ethoxyresoruﬁn internal standard (10 nM ﬁnal concentration)
was added to the solution. 7-hydroxycoumarin was quantiﬁed
using an HPLC-SCIEX/ABI 4000 Q-Trap mass spectrometer (Applied
Biosystems, USA).
2.5. Cell treatment
Seven days after seeding, HepaRG cells were incubated at
37 C with bioactive CYP-independent NNKOAc (50 lM) or
bioactive CYP-dependent NNK (100 lM) dissolved in DMSO (ﬁnal
concentration 0.5%) in culture medium for 3 h or 12 h, respectively.
Cells were also exposed to 750 lM MMS prepared in phosphate
buffered-saline (1 PBS, Invitrogen by life technologies, Spain)
for 1 h, as a positive control to ensure the assay worked properly.
Untreated and DMSO-treated HepaRG cells were also assessed
as negative controls. Additionally, in order to determine the effect
of PPITC, nicotine, and cotinine inhibition on CYP-dependent NNK
bioactivation, HepaRG cells were pre-incubated with PPITC
(10 lM) or Cotinine (0.01 lM, 0.1 lM, 1.0 lM, and 10 lM) for
30 min before the addition of NNKOAc or NNK in order to prime
the metabolic enzymes. NNKOAc or NNK were then added and
the incubation continued for a total of 3 h or 12 h, respectively.
2.6. Alkaline COMET assay
The Alkaline COMET assay was based on the methods described
by Tice et al. (2000), Thorne et al. (2009) and the COMET assay
interest group (http://www.cometassay.com) with slight modiﬁca-
tions. Cells were trypsinised (1% Trypsin-EDTA), transferred to
eppendorf tubes and centrifuged (1 min, 300g). Cell pellets were
resuspended in 0.6% low melting-point agarose at 37 C. A fraction
of the cell suspension was used to measure viability using the
trypan blue dye exclusion method. The cell/agarose suspension
was placed on Superfrost slides (Menzel-Glaser, Thermo Fisher
Scientiﬁc, Germany) pre-coated with 1.0% collagen (PureCol,
NUTACON B.V., Holland) to facilitate gel adherence and air-dried
for 24 h prior to coating with 1.5% normal melting-point agarose.
Slides were placed in lysis buffer (2.5 M NaCl, 100 mM EDTA,
10 mM Trizma, 0.2 M NaOH, 10% DMSO & 1% Triton X-100, pH
10) for at least 24 h at 4 C then gently rinsed (3  5 min) with
enzyme reaction buffer (40 mM HEPES, 0.1 M KCl, 0.5 mM EDTA,
0.2 mg/mL BSA, pH 8) at room temperature (RT). Electrophoresiswas performed for 20 min at 25 constant volts at 4 C. After elec-
trophoresis, slides were removed from the tanks and placed in a
staining rack for neutralisation. Approximately 3.5 mL of
neutralisation buffer (0.4 M Trizma, pH 7.5) were pipetted onto
each slide. This process was repeated three times for 5 min. The
excess of neutralisation buffer was removed and the slides were
air dried for at least 12 h at RT prior to staining and scoring. Imme-
diately prior to scoring, 20 lL of VECTASHIELD Mounting Medium
containing DAPI (1.5 lg/mL, Vector Laboratories Inc.) was applied
to slides & nuclei visualized using 20 magniﬁcation of a ﬂuores-
cence microscope ﬁtted with an appropriate ﬁlter. Approximately
100 nuclei per slide were assessed with a minimum of two slides
per tested condition performed in a minimum of 3 independent
replicates. DNA damage was determined using COMET Assay IV
image analysis software (Perceptive Instruments, Harverhill, UK)
and the percentage of tail intensity was recorded. At least three
independent assays were performed.
2.7. Statistical analysis
Data were analyzed by using the parametric statistical approach
published by Bright et al. (2011). The median by plate of the loga-
rithmic tail intensity were analyzed in a mixed model in Minitab
16 software (Minitab Ltd, Coventry, UK) with treatment as ﬁxed
effect and run as random effect, differences between the treatment
variances was speciﬁed. Post-hoc multiple comparisons were
adjusted by Tukey’s. Individual value plots were generated using
SAS JMP Genomics 6.0 (SAS Institute, Cary (NC), USA). Mean fold
increases were calculated from the back-transformed median of
the log tail intensity for each slide divided by the mean of the
back-transformed medians of the log tail intensity of the reference
condition (Bright et al., 2011). Fold change signiﬁcance was tested
using a one sample t-test assessing no difference with 1 fold
change in DNA damage relative to a reference condition. Interval
plots were created with Minitab 16 statistical software.
3. Results
3.1. Selection of CYP competent cell system
mRNA expression proﬁling for 41 xenobiotic metabolizing
enzymes in the hepatic cell line HepaRG (3 independent repeats,
7 day cultures) and primary human bronchial epithelial cells
(HBECs) (28 days culture, 3 donors) was performed to evaluate
the diversity of CYPs and other metabolic genes expressed in those
cell types (Fig. 2). One normal pooled human lung mRNA was also
used for comparison. The heat map (Fig. 2) shows a greater
diversity of CYP mRNA expression in HepaRG. Amongst others
and by intensity level (DCTs), CYP3A4, 3A5, 2E1, 2B6, 2C9, 2B7,
1A1, 1B1, 1A2, 2D6 of which 3A4, 2E1, 2B6, 1A1, 1A2, have been
involved with NNK bioactivation. CYP2A6 Ct values were close to
the exclusion threshold for expression, but were below this
threshold in all our replicate experiments in HepaRG indicating
expression but at a low level. CYP2A13 was detected in HBECs
but was considered not expressed in HepaRG based on high CTs
values and at least one replicate over the exclusion threshold for
expression. We further tested coumarin 7-hydroxylation activity,
a reporter probe for CYP2A6/2A13 activity in HepaRG and
compared this activity with previous data we obtained with HBECs,
A549 and published data in normal hepatocytes (Table 1). Couma-
rin 7-hydroxylation activity was recorded in HepaRG at day 7 in
culture (1.13 pmol/mg prot/min) and was approximately 4 times
lower than the median value reported for normal human hepato-
cyte (Donato et al., 2000) (Table 1) and within the range of activity
measured in HBECs (Table 1). 7-Hydroxycoumarin activity was
also inhibited by 8-methoxypsoralen, a known selective inhibitor
Fig. 2. Hierarchical cluster representing the gene expression proﬁles of 41 selected metabolic genes tested in HBECs (28 days in culture) (3 subjects, 1, 2, and 3) and three
independent replicates for HepaRG (7 days in culture). A representative lung proﬁle was also included (pooled mRNA 5 subjects). Columns represent individual samples and
rows represent genes. Green, black, and red indicate high signal intensity, moderate signal intensity and low to no signal in normalized gene expression data (DCt),
respectively.
Table 1
Comparative coumarin 7-hydroxylation activity in primary human bronchial epithelial cells (HEBCs) from 3 donors (D1, D2, and D3), A549 cells, and HepaRG cells. HepaRG
activity was measured at after 7 days recovery corresponding to the same time point used for the COMET assay. 8-methoxypsoralen (8-MOP) was used as inhibitor of CYP2A6/
CYP2A13. Results are presented as mean of three measurements ± standard deviation.
Cells 7-Hydroxycoumarin (pmol/mg prot/min) Reference
No inhibitor 8-MOP
A549 0.003 ± 0.001 0.003 ± 0.001 Newland et al. (2011)
HBECs D1 (28 days) 1.264 ± 0.05 0.275 ± 0.08
HBECs D2 (28 days) 4.289 ± 1.9 0.681 ± 0.3
HBECs D3 (28 days) 0.088 ± 0.04 0.011 ± 0.005
HepaRG (7 days) 1.13 ± 0.3 0.04 ± 0.006 This study
Hepatocytes (n = 16) 1–20 (median 3.85) NA Donato et al. (2000)
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of CYP expression and coumarin hydroxylation activity, HepaRG
cells were chosen to study CYP-dependent NNK-induced DNA
damage.3.2. Selection of NNK and NNKOAc dose
In this work we decided to use the COMET assay to study single
and double DNA strand breaks in HepaRG (7 days culture) in the
P. Ordonez et al. / Toxicology in Vitro 28 (2014) 1329–1337 1333presence of NNK. Since no COMET assay studies were previously
reported in HepaRG with NNK, we ﬁrst investigated the conditions
at which NNK gave statistically signiﬁcant DNA damage without
affecting cell viability. A 15.7% median (21% mean) tail intensity
was observed for 100 lM NNK for 12 h (Supplementary Fig. 1A
and Table 1A), higher concentrations did not yield increased DNA
damage. NNKOAc was also used as a CYP-independent control for
NNK-induced-DNA damage. NNKOAc produces the same reactive
intermediates as NNK but the reaction is catalyzed by the ubiqui-
tous esterases, not by CYPs (Peterson et al., 1991). Due to the high
reactivity and genotoxic driven cytotoxicity of NNKOAc a lower
dose of 25 lM NNKOAc for 3 h was selected to give DNA damage
within a close range of NNK (24% median, 29% mean tail intensity)
(Supplementary Fig. 1B and Table 1B). Finally, we also included a
nicotine, cotinine, and b-nicotyrine (10 lM) control only and an
MMS positive control. No difference was observed between
nicotine, cotinine, b-nicotyrine and the DMSO condition
(Supplementary Fig. 2 and Table 2). The Trypan-blue exclusion cell
viability assay for all the dose-range tested was comprised
between 95% and 100%.Fig. 3. Single value plots for COMET % tail intensity for HepaRG cells incubated with
NNK (100 lM) and a dose range of nicotine (A), cotinine (B) (0.01–10 lM), and b-
nicotyrine (C) (5–50 lM) for 12 h. 0.5% DMSO is the vector control. Median values
for % tail intensity for each condition tested are shown in red ().3.3. Inhibition of NNK-induced DNA strand breaks in the presence of
nicotine, cotinine, and b-nicotyrine
To test our hypothesis that the inhibition of CYPs by nicotine,
cotinine or a cotinine-derived metabolite has the potential to
reduce NNK bioactivation and consequently NNK-driven DNA
strand breaks, HepaRG (7 days culture) were incubated with NNK
and increasing doses of nicotine, cotinine (0.01–10 lM), and
b-nicotyrine (5 and 50 lM). A COMET assay was performed and
results were compared with non-treated and DMSO controls.
Single value plots for the tail intensity are presented in Fig. 3A–C
and show the distribution of the data points for each condition
tested. Tukey group comparisons are presented in Table 2A–C.
No differences in DNA damage were observed between the
NNK + 10 lM nicotine, cotinine, 5 lM b-nicotyrine and the non-
treated and DMSO controls (Fig. 3 and Table 2). In order to account
for the biological relevance of the changes in DNA tail intensity,
fold changes and conﬁdence intervals relative to DMSO control
are also presented in Fig. 4A–C. To demonstrate the CYP-depen-
dency of the previous observation, HepaRG cells were pre-incu-
bated with 10 lM nicotine and cotinine for 9 h and for a further
3 h with nicotine or cotinine and NNKOAc to reach a total of
12 h. NNKOAc is an esterase-dependent, CYP-independent acti-
vated form of NNK and therefore nicotine and cotinine should
not inhibit NNKOAc-induced DNA damage. As hypothesised,
NNKOAc-induced DNA strand break was not affected by the
presence of nicotine or cotinine (Fig. 5A and B, Table 3). To further
conﬁrm that NNK-induced DNA damage was CYP2 or CYP1A
dependent, a PPITC control was included. PPITC is an isothiocya-
nate that efﬁciently inhibits multiple CYPs (2A6, 2A13, 2E1, 2B6,
1A2) (Hamilton and Teel, 1996; Nakajima et al., 2001; von
Weymarn et al., 2007). NNK-induced DNA damaged was inhibited
by PPITC while NNKOAc-induced DNA break was not affected by
PPITC (Figs. 3–5 and Tables 2 and 3).4. Discussion
In this study, we asked if the interaction of nicotine with meta-
bolic processes common with NNK metabolism translates into
reduced NNK-dependent DNA strand breaks in CYP-competent
hepatic cell cultures. The toxicological endpoint selected was
DNA strand breaks measured using the COMET assay.
A critical point in our experimental design was to select a cell
system which had retained the expression and activity ofmetabolic enzymes reported to be involved in NNK bioactivation
such as CYPs. Since NNK is a more potent lung carcinogen than
liver carcinogen, metabolically competent airway cells would be
the ideal test system. Primary HBECs are better models than
lung-derived cell lines because as shown in this study (Fig. 2)
and others (Newland et al., 2011), they express CYP2A13 a key
enzyme in nitrosamines activation in the respiratory tract (Zhang
et al., 2007). However, implementing their use in a COMET assay
is difﬁcult because of interindividual variability in the metabolic
activity and the morphology of the culture which forms multiple
Table 2
Pairwise comparison (Tukey test) for signiﬁcant differences between different NNK
treatments at 95% conﬁdence. A. NNK + Nicotine (Nik), B. NNK + Cotinine (Cot), C.
NNK + b-nicotyrine (b-Nic); PPITC was used as a CYP2A/1A/2E/2B control inhibitor.
NT is the non-treated control. ‘‘n’’ indicates the total number of slides counted from a
minimum of 3 independent experiments with the overall total nuclei counted. The
‘‘median’’ value is the median % tail intensity for all counted nuclei. Pairwise
comparison was performed using the general linear model and the mean of the
median of the log transformed data for each independent experiment (to account for
the data distribution). Treatment results that do not share a letter (‘‘Grouping’’) are
signiﬁcantly different.
Treatment n Nuclei Median Grouping
A
100 lM NNK 14 1353 11.32 A
100 lM NNK + 0.01 lM Nic 14 1385 7.07 A B
100 lM NNK + 0.1 lM Nic 14 1348 3.92 A B C
100 lM NNK + 1 lM Nic 14 1372 2.73 B C D
100 lM NNK + PPITC 14 1387 0.94 C D E
100 lM NNK + 10 lM Nic 14 1365 1.0 D E
NT 14 1373 0.31 E
0.5% DMSO 14 1399 0.50 E
B
100 lM NNK 16 1540 16.40 A
100 lM NNK + 0.01 lM Cot 12 1142 3.42 A B
100 lM NNK + 0.1 lM Cot 12 1133 7.92 B C
100 lM NNK + 1 lM Cot 15 1386 2.50 B C D
100 lM NNK + PPITC 21 2031 1.77 C D E
100 lM NNK + 10 lM Cot 15 1386 1.01 C D E
NT 16 1552 1.34 D E
0.5% DMSO 14 1375 0.86 E
C
100 lM NNK 6 592 15.65 A
100 lM NNK + 50 lM b-Nic 6 581 2.22 B
100 lM NNK + 10 lM PPITC 6 586 2.57 B
100 lM NNK + 5 lM b-Nic 6 593 3.53 B
NT 6 593 1.45 B
0.5% DMSO 6 596 2.14 B
Fig. 4. Interval plots: 95% conﬁdence intervals of the mean of the medians and p-
values for one sample t-test for fold change different of 1 DNA tail intensity
relative to DMSO control (calculated from back-transformed data). (A) NNK + nic-
otine, (B) NNK + cotinine and (C) NNK + b-nicotyrine.
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cell layers is an issue in COMET due to uneven exposure of cells
to the test compound. In contrast the human hepatic-derived cell
line HepaRG was shown to express a diverse array of CYPs relevant
to NNK-bioactivation such as CYP1A2, CYP1A1, CYP3A4, CYP2B6,
CYP2E1 and low levels of CYP2A6 (Fig. 2). Coumarin 7-hydroxyl-
ation activity (Table 1), bupropion hydroxylation, and ethoxyreso-
rudﬁn o-dealkylation (Garcia-Canton et al., 2013; Gerets et al.,
2012) indicative of at least CYP2A, 2B, and CYP1A activity have
been demonstrated in this cell line. The coumarin 7-hydroxylation
activity that was recorded in our study contrasted with the low
CYP2A6 mRNA expression at 7 days in HepaRG. This could be
attributed to post-transcriptional regulation of CYP2A6 which has
been described previously at the mRNA and enzymatic level
(Ariyoshi et al., 2001; Gilmore et al., 2001). In addition to a favor-
able CYP proﬁle, HepaRG cells are grown as a monolayer which is
important for the consistency of COMET results and thus offer an
advantage. Therefore, we decided to use HepaRG as a ﬁrst step in
the investigation of nicotine and NNK interaction by COMET. Using
HepaRG, we were able to detect statistically signiﬁcant DNA strand
breaks when cells were incubated with 100 lM NNK for 12 h. The
damage was moderate (11–16% median tail intensity) since DNA
strand break is only one of multiple mechanisms through which
NNK exerts its genotoxic activity. In addition, the CYP activity of
HepaRG might not reﬂect the activity found in normal liver. Hang
et al., have reported signiﬁcant NNK-mediated DNA damage
(8–9%) in HepG2 but at the much lower concentration of
0.1 lM of NNK (Hang et al., 2013). This difference in sensitivity is
likely to arise from the different statistical approaches that were
used to analyze the data and the cell type (Gerets et al., 2012).
Our analysis followed the ‘‘Recommendations on the statisticalanalysis of the COMET assay’’ designed by the Statistician in the
Pharmaceutical Industry Toxicology Special Interest Group (PSI)
(Bright et al., 2011). If we had applied a similar statistical method
as reported in Hang et al., we would also have had a signiﬁcant
DNA-damage response at our lowest tested dose of NNK. We think
however that the PSI method is statistically more robust since
often COMET data is not normally distributed which should be
Fig. 5. (A) Single value plots for COMET % tail intensity for HepaRG cells pre-
incubated 9 h with nicotine, cotinine, and PPITC (10 lM) and a further 3 h after
addition of NNKOAc (25 lM). 0.5% DMSO is the vector control. Median values for %
tail intensity for each condition tested are shown in red (). (B) Interval plots: 95%
conﬁdence intervals of the mean of the medians and p-values for one sample t-test
for fold change different of 1 DNA tail intensity relative to NNKOAc control
(calculated from back-transformed data).
Table 3
Pairwise comparison (Tukey test) for signiﬁcant differences between different
NNKOAc treatments at 95% conﬁdence. DNA damage was tested after incubation
with nicotine (Nic), cotinine (Cot) and PPITC; NT is the non-treated control. ‘‘n’’
indicates the total number of slides counted from a minimum of 3 independent
experiments with the overall total nuclei counted. The ‘‘median’’ value is the median
% tail intensity for all counted nuclei. Pairwise comparison was performed using the
general linear model and the mean of the median of the log transformed data for each
independent experiment (to account for the data distribution). Treatment results that
do not share a letter (‘‘Grouping’’) are signiﬁcantly different.
Treatment n Nuclei Median Grouping
25 lM NNKOAc 6 595 26.55 A
25 lM NNKOAc + 10 lM Nic 6 600 23.85 A
25 lM NNKOAc + 10 lM Cot 6 564 26.81 A
25 lM NNKOAc + 10 lM PPITC 6 592 29.15 A
NT 6 593 0.17 B
0.5% DMSO 6 590 0.24 B
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optimizing the COMET condition to obtain minimum background
DNA strand break is critical to the sensitivity of the assay.Background DNA strand break can arise from the trypsin treatment
and we have seen some variation from experiment to experiment.
When nicotine and cotinine were co-incubated with NNK no
statistical differences in the level of DNA strand break could be
detected with the DMSO control group (Table 2A and B). Nicotine
and cotinine alone did not increase or decrease DNA strand break
(Supplementary Table 2). The reduction in NNK-dependent DNA
strand break in the presence of cotinine and nicotine was dose-
dependent. Fold changes relative to the DMSO control, taking into
account conﬁdence intervals showed a 2 fold increase DNA tail
intensity and a p-value of 0.13 for 100 lM NNK + 10 lM Nicotine
treatment indicating that for this nicotine dose we cannot con-
clude whether the DMSO control and the test are different
(Fig. 4A). Cotinine seemed to be a stronger inhibitor of NNK-depen-
dent DNA damage since no difference with control could be
detected with doses as low as 1 lM (2.7 fold change p-value = 0.1)
(Fig. 4B). However with fold changes higher than 2, it is reasonable
to assume that inhibition is not complete and that this can still be
of biological relevance. A similar effect was observed when NNK
was incubated with PPITC, a CYP inhibitor active towards CYP2A,
B, E and 1A enzymes, which show fold changes in DNA tail inten-
sity of no more than or lower than 2 compared to the DMSO con-
trol (Fig. 4A and B). The data is robust since statistical signiﬁcance
was established from a minimum of 1000 cell nuclei counted from
at least 3 independent experiments which included a minimum of
2 slides each. b-Nicotyrine, another reported inhibitor of the CYP2A
enzymes (Kramlinger et al., 2012), was also protecting against DNA
strand break in HepaRG cells at the lowest tested concentration
(5 lM) (Table 2C, Fig. 4C), but we did not test a wider dose range.
In contrast, when the HepaRG cells were incubated with NNKOAc,
a CYP-independent reactive form of NNK, no reduction in DNA
strand break was measured in the presence of PPITC, nicotine,
and cotinine as shown by the tail intensity fold changes between
1.1 and 0.91 relative to the NNKOAc only control (Fig. 5B). The con-
centration of NNKOAc used (25 lM) was below the dose that gave
maximum DNA-damage (50–100 lM) based on our dose-range
assessment which meant that the absence of protection with
nicotine and cotinine was not due to a plateau effect. These results
indicate that nicotine and cotinine inhibit NNK-induced DNA sin-
gle and double strand breaks in HepaRG and that the mechanism
is CYP-dependent since NNKOAc is not affected. Those results are
in agreement with in vivo results presented by Brown et al., which
also showed that NNK-dependent DNA methylation was inhibited
by cotinine in A/J mice (Argentin and Cicchetti, 2004; Brown et al.,
1999). Importantly, we did not observe a synergistic deleterious
effect on DNA damage following co-incubation of nicotine with
NNK and there is no evidence that a protective effect happens
in vivo, at least in the lung (Murphy et al., 2011). Our results have
to be considered with caution since hepatic-derived cells were
used with activity of CYPs shown to be lower than normal hepatic
cells (Gerets et al., 2012). It would be of interest to optimize the
COMET assay with primary human lung epithelial cells where
CYP2A13 is expressed although this is likely to require extensive
assay optimisation. Furthermore, due to the diverse CYP expression
proﬁle of HepaRG our experimental design did not allow the iden-
tiﬁcation of speciﬁc CYPs target but should be considered as a ﬁrst
step towards a more detailed investigation. The NNK dose that was
used was relatively high, however the lowest doses of nicotine and
the doses of cotinine were within ranges of what can be found in
the plasma of smokers. It should also be considered that nicotine
or a nicotine metabolite could have an antagonistic effect, on one
hand inhibiting some CYP enzymes and on the other hand promot-
ing an anti-apoptotic response through receptor binding (Nishioka
et al., 2010). Finally, it is also important to remember that
DNA-strand breaks are only one of the many mechanisms through
which NNK exerts its genotoxic activity.
1336 P. Ordonez et al. / Toxicology in Vitro 28 (2014) 1329–1337In conclusion, we have developed and applied a robust protocol
to assess DNA damage by COMET in HepaRG cells, a cell line that
shares greater similarity with normal human hepatocytes. Using
the COMET assay, we showed that nicotine, cotinine or a
metabolite of cotinine can protect against NNK-induced DNA
damage in a hepatic-derived cell line, possibly by inhibiting CYP
enzymes. Importantly, this highlights the current limitations of
the classical paradigm of single toxicant assessment when a
complex mixture such as tobacco smoke is considered. It would
be of interest to develop a similar approach using a system more
physiologically relevant such as 3D primary lung epithelial
cultures.
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